-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED Announces China NDA Acceptance And Priority Review For Fanregratinib Supported By Phase II Registration Trial Results

Benzinga·12/29/2025 08:37:09
语音播报
  • NDA supported by results from a Phase II registration trial in China —
  • — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in compariso